Circulating Tumor Cell Market, Global Outlook and Forecast 2022-2028

April 2022 | 116 pages | ID: C5E12C443B22EN
Market Monitor Global

Abstracts

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

This report contains market size and forecasts of Circulating Tumor Cell in Global, including the following market information:

Global Circulating Tumor Cell Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Circulating Tumor Cell market was valued at 6382.4 million in 2021 and is projected to reach US$ 13660 million by 2028, at a CAGR of 11.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

CTC Enrichment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Circulating Tumor Cell include Menarini-Silicon Biosystems, Qiagen?Adnagen?, Clearbridge Biomedics, Celsee, Fluidigm, ApoCell, Greiner Bio-one, Advanced Cell Diagnostics and Aviva Biosciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Circulating Tumor Cell companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Circulating Tumor Cell Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Circulating Tumor Cell Market Segment Percentages, by Type, 2021 (%)

• CTC Enrichment
• CTC Detection
• CTC Analysis

Global Circulating Tumor Cell Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Circulating Tumor Cell Market Segment Percentages, by Application, 2021 (%)

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Others

Global Circulating Tumor Cell Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Circulating Tumor Cell Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Circulating Tumor Cell revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Circulating Tumor Cell revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Menarini-Silicon Biosystems
• Qiagen?Adnagen?
• Clearbridge Biomedics
• Celsee
• Fluidigm
• ApoCell
• Greiner Bio-one
• Advanced Cell Diagnostics
• Aviva Biosciences
• Fluxion Biosciences
• Sysmex
• Epic Sciences
• Cynvenio
• CytoTrack
• Ikonisys
• Vortex BioSciences
• Gilupi
• Biocept
• ScreenCell
• ANGLE

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Circulating Tumor Cell Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Circulating Tumor Cell Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CIRCULATING TUMOR CELL OVERALL MARKET SIZE

2.1 Global Circulating Tumor Cell Market Size: 2021 VS 2028
2.2 Global Circulating Tumor Cell Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Circulating Tumor Cell Players in Global Market
3.2 Top Global Circulating Tumor Cell Companies Ranked by Revenue
3.3 Global Circulating Tumor Cell Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor Cell Companies in Global Market, by Revenue in 2021
3.5 Global Companies Circulating Tumor Cell Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor Cell Players in Global Market
  3.6.1 List of Global Tier 1 Circulating Tumor Cell Companies
  3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor Cell Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Circulating Tumor Cell Market Size Markets, 2021 & 2028
  4.1.2 CTC Enrichment
  4.1.3 CTC Detection
  4.1.4 CTC Analysis
4.2 By Type - Global Circulating Tumor Cell Revenue & Forecasts
  4.2.1 By Type - Global Circulating Tumor Cell Revenue, 2017-2022
  4.2.2 By Type - Global Circulating Tumor Cell Revenue, 2023-2028
  4.2.3 By Type - Global Circulating Tumor Cell Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Circulating Tumor Cell Market Size, 2021 & 2028
  5.1.2 Breast Cancer
  5.1.3 Prostate Cancer
  5.1.4 Colorectal Cancer
  5.1.5 Others
5.2 By Application - Global Circulating Tumor Cell Revenue & Forecasts
  5.2.1 By Application - Global Circulating Tumor Cell Revenue, 2017-2022
  5.2.2 By Application - Global Circulating Tumor Cell Revenue, 2023-2028
  5.2.3 By Application - Global Circulating Tumor Cell Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Circulating Tumor Cell Market Size, 2021 & 2028
6.2 By Region - Global Circulating Tumor Cell Revenue & Forecasts
  6.2.1 By Region - Global Circulating Tumor Cell Revenue, 2017-2022
  6.2.2 By Region - Global Circulating Tumor Cell Revenue, 2023-2028
  6.2.3 By Region - Global Circulating Tumor Cell Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Circulating Tumor Cell Revenue, 2017-2028
  6.3.2 US Circulating Tumor Cell Market Size, 2017-2028
  6.3.3 Canada Circulating Tumor Cell Market Size, 2017-2028
  6.3.4 Mexico Circulating Tumor Cell Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Circulating Tumor Cell Revenue, 2017-2028
  6.4.2 Germany Circulating Tumor Cell Market Size, 2017-2028
  6.4.3 France Circulating Tumor Cell Market Size, 2017-2028
  6.4.4 U.K. Circulating Tumor Cell Market Size, 2017-2028
  6.4.5 Italy Circulating Tumor Cell Market Size, 2017-2028
  6.4.6 Russia Circulating Tumor Cell Market Size, 2017-2028
  6.4.7 Nordic Countries Circulating Tumor Cell Market Size, 2017-2028
  6.4.8 Benelux Circulating Tumor Cell Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Circulating Tumor Cell Revenue, 2017-2028
  6.5.2 China Circulating Tumor Cell Market Size, 2017-2028
  6.5.3 Japan Circulating Tumor Cell Market Size, 2017-2028
  6.5.4 South Korea Circulating Tumor Cell Market Size, 2017-2028
  6.5.5 Southeast Asia Circulating Tumor Cell Market Size, 2017-2028
  6.5.6 India Circulating Tumor Cell Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Circulating Tumor Cell Revenue, 2017-2028
  6.6.2 Brazil Circulating Tumor Cell Market Size, 2017-2028
  6.6.3 Argentina Circulating Tumor Cell Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Circulating Tumor Cell Revenue, 2017-2028
  6.7.2 Turkey Circulating Tumor Cell Market Size, 2017-2028
  6.7.3 Israel Circulating Tumor Cell Market Size, 2017-2028
  6.7.4 Saudi Arabia Circulating Tumor Cell Market Size, 2017-2028
  6.7.5 UAE Circulating Tumor Cell Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Menarini-Silicon Biosystems
  7.1.1 Menarini-Silicon Biosystems Corporate Summary
  7.1.2 Menarini-Silicon Biosystems Business Overview
  7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cell Major Product Offerings
  7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.1.5 Menarini-Silicon Biosystems Key News
7.2 Qiagen(Adnagen)
  7.2.1 Qiagen(Adnagen) Corporate Summary
  7.2.2 Qiagen(Adnagen) Business Overview
  7.2.3 Qiagen(Adnagen) Circulating Tumor Cell Major Product Offerings
  7.2.4 Qiagen(Adnagen) Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.2.5 Qiagen(Adnagen) Key News
7.3 Clearbridge Biomedics
  7.3.1 Clearbridge Biomedics Corporate Summary
  7.3.2 Clearbridge Biomedics Business Overview
  7.3.3 Clearbridge Biomedics Circulating Tumor Cell Major Product Offerings
  7.3.4 Clearbridge Biomedics Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.3.5 Clearbridge Biomedics Key News
7.4 Celsee
  7.4.1 Celsee Corporate Summary
  7.4.2 Celsee Business Overview
  7.4.3 Celsee Circulating Tumor Cell Major Product Offerings
  7.4.4 Celsee Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.4.5 Celsee Key News
7.5 Fluidigm
  7.5.1 Fluidigm Corporate Summary
  7.5.2 Fluidigm Business Overview
  7.5.3 Fluidigm Circulating Tumor Cell Major Product Offerings
  7.5.4 Fluidigm Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.5.5 Fluidigm Key News
7.6 ApoCell
  7.6.1 ApoCell Corporate Summary
  7.6.2 ApoCell Business Overview
  7.6.3 ApoCell Circulating Tumor Cell Major Product Offerings
  7.6.4 ApoCell Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.6.5 ApoCell Key News
7.7 Greiner Bio-one
  7.7.1 Greiner Bio-one Corporate Summary
  7.7.2 Greiner Bio-one Business Overview
  7.7.3 Greiner Bio-one Circulating Tumor Cell Major Product Offerings
  7.7.4 Greiner Bio-one Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.7.5 Greiner Bio-one Key News
7.8 Advanced Cell Diagnostics
  7.8.1 Advanced Cell Diagnostics Corporate Summary
  7.8.2 Advanced Cell Diagnostics Business Overview
  7.8.3 Advanced Cell Diagnostics Circulating Tumor Cell Major Product Offerings
  7.8.4 Advanced Cell Diagnostics Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.8.5 Advanced Cell Diagnostics Key News
7.9 Aviva Biosciences
  7.9.1 Aviva Biosciences Corporate Summary
  7.9.2 Aviva Biosciences Business Overview
  7.9.3 Aviva Biosciences Circulating Tumor Cell Major Product Offerings
  7.9.4 Aviva Biosciences Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.9.5 Aviva Biosciences Key News
7.10 Fluxion Biosciences
  7.10.1 Fluxion Biosciences Corporate Summary
  7.10.2 Fluxion Biosciences Business Overview
  7.10.3 Fluxion Biosciences Circulating Tumor Cell Major Product Offerings
  7.10.4 Fluxion Biosciences Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.10.5 Fluxion Biosciences Key News
7.11 Sysmex
  7.11.1 Sysmex Corporate Summary
  7.11.2 Sysmex Business Overview
  7.11.3 Sysmex Circulating Tumor Cell Major Product Offerings
  7.11.4 Sysmex Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.11.5 Sysmex Key News
7.12 Epic Sciences
  7.12.1 Epic Sciences Corporate Summary
  7.12.2 Epic Sciences Business Overview
  7.12.3 Epic Sciences Circulating Tumor Cell Major Product Offerings
  7.12.4 Epic Sciences Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.12.5 Epic Sciences Key News
7.13 Cynvenio
  7.13.1 Cynvenio Corporate Summary
  7.13.2 Cynvenio Business Overview
  7.13.3 Cynvenio Circulating Tumor Cell Major Product Offerings
  7.13.4 Cynvenio Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.13.5 Cynvenio Key News
7.14 CytoTrack
  7.14.1 CytoTrack Corporate Summary
  7.14.2 CytoTrack Business Overview
  7.14.3 CytoTrack Circulating Tumor Cell Major Product Offerings
  7.14.4 CytoTrack Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.14.5 CytoTrack Key News
7.15 Ikonisys
  7.15.1 Ikonisys Corporate Summary
  7.15.2 Ikonisys Business Overview
  7.15.3 Ikonisys Circulating Tumor Cell Major Product Offerings
  7.15.4 Ikonisys Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.15.5 Ikonisys Key News
7.16 Vortex BioSciences
  7.16.1 Vortex BioSciences Corporate Summary
  7.16.2 Vortex BioSciences Business Overview
  7.16.3 Vortex BioSciences Circulating Tumor Cell Major Product Offerings
  7.16.4 Vortex BioSciences Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.16.5 Vortex BioSciences Key News
7.17 Gilupi
  7.17.1 Gilupi Corporate Summary
  7.17.2 Gilupi Business Overview
  7.17.3 Gilupi Circulating Tumor Cell Major Product Offerings
  7.17.4 Gilupi Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.17.5 Gilupi Key News
7.18 Biocept
  7.18.1 Biocept Corporate Summary
  7.18.2 Biocept Business Overview
  7.18.3 Biocept Circulating Tumor Cell Major Product Offerings
  7.18.4 Biocept Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.18.5 Biocept Key News
7.19 ScreenCell
  7.19.1 ScreenCell Corporate Summary
  7.19.2 ScreenCell Business Overview
  7.19.3 ScreenCell Circulating Tumor Cell Major Product Offerings
  7.19.4 ScreenCell Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.19.5 ScreenCell Key News
7.20 ANGLE
  7.20.1 ANGLE Corporate Summary
  7.20.2 ANGLE Business Overview
  7.20.3 ANGLE Circulating Tumor Cell Major Product Offerings
  7.20.4 ANGLE Circulating Tumor Cell Revenue in Global Market (2017-2022)
  7.20.5 ANGLE Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Circulating Tumor Cell Market Opportunities & Trends in Global Market
Table 2. Circulating Tumor Cell Market Drivers in Global Market
Table 3. Circulating Tumor Cell Market Restraints in Global Market
Table 4. Key Players of Circulating Tumor Cell in Global Market
Table 5. Top Circulating Tumor Cell Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Circulating Tumor Cell Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Circulating Tumor Cell Revenue Share by Companies, 2017-2022
Table 8. Global Companies Circulating Tumor Cell Product Type
Table 9. List of Global Tier 1 Circulating Tumor Cell Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Circulating Tumor Cell Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Circulating Tumor Cell Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Circulating Tumor Cell Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Circulating Tumor Cell Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Circulating Tumor Cell Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Circulating Tumor Cell Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Circulating Tumor Cell Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Circulating Tumor Cell Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Circulating Tumor Cell Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Circulating Tumor Cell Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Circulating Tumor Cell Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Circulating Tumor Cell Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Circulating Tumor Cell Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Circulating Tumor Cell Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Circulating Tumor Cell Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Circulating Tumor Cell Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Circulating Tumor Cell Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Circulating Tumor Cell Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Circulating Tumor Cell Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Circulating Tumor Cell Revenue, (US$, Mn), 2023-2028
Table 30. Menarini-Silicon Biosystems Corporate Summary
Table 31. Menarini-Silicon Biosystems Circulating Tumor Cell Product Offerings
Table 32. Menarini-Silicon Biosystems Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 33. Qiagen?Adnagen? Corporate Summary
Table 34. Qiagen?Adnagen? Circulating Tumor Cell Product Offerings
Table 35. Qiagen?Adnagen? Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 36. Clearbridge Biomedics Corporate Summary
Table 37. Clearbridge Biomedics Circulating Tumor Cell Product Offerings
Table 38. Clearbridge Biomedics Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 39. Celsee Corporate Summary
Table 40. Celsee Circulating Tumor Cell Product Offerings
Table 41. Celsee Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 42. Fluidigm Corporate Summary
Table 43. Fluidigm Circulating Tumor Cell Product Offerings
Table 44. Fluidigm Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 45. ApoCell Corporate Summary
Table 46. ApoCell Circulating Tumor Cell Product Offerings
Table 47. ApoCell Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 48. Greiner Bio-one Corporate Summary
Table 49. Greiner Bio-one Circulating Tumor Cell Product Offerings
Table 50. Greiner Bio-one Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 51. Advanced Cell Diagnostics Corporate Summary
Table 52. Advanced Cell Diagnostics Circulating Tumor Cell Product Offerings
Table 53. Advanced Cell Diagnostics Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 54. Aviva Biosciences Corporate Summary
Table 55. Aviva Biosciences Circulating Tumor Cell Product Offerings
Table 56. Aviva Biosciences Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 57. Fluxion Biosciences Corporate Summary
Table 58. Fluxion Biosciences Circulating Tumor Cell Product Offerings
Table 59. Fluxion Biosciences Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 60. Sysmex Corporate Summary
Table 61. Sysmex Circulating Tumor Cell Product Offerings
Table 62. Sysmex Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 63. Epic Sciences Corporate Summary
Table 64. Epic Sciences Circulating Tumor Cell Product Offerings
Table 65. Epic Sciences Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 66. Cynvenio Corporate Summary
Table 67. Cynvenio Circulating Tumor Cell Product Offerings
Table 68. Cynvenio Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 69. CytoTrack Corporate Summary
Table 70. CytoTrack Circulating Tumor Cell Product Offerings
Table 71. CytoTrack Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 72. Ikonisys Corporate Summary
Table 73. Ikonisys Circulating Tumor Cell Product Offerings
Table 74. Ikonisys Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 75. Vortex BioSciences Corporate Summary
Table 76. Vortex BioSciences Circulating Tumor Cell Product Offerings
Table 77. Vortex BioSciences Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 78. Gilupi Corporate Summary
Table 79. Gilupi Circulating Tumor Cell Product Offerings
Table 80. Gilupi Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 81. Biocept Corporate Summary
Table 82. Biocept Circulating Tumor Cell Product Offerings
Table 83. Biocept Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 84. ScreenCell Corporate Summary
Table 85. ScreenCell Circulating Tumor Cell Product Offerings
Table 86. ScreenCell Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)
Table 87. ANGLE Corporate Summary
Table 88. ANGLE Circulating Tumor Cell Product Offerings
Table 89. ANGLE Circulating Tumor Cell Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Circulating Tumor Cell Segment by Type in 2021
Figure 2. Circulating Tumor Cell Segment by Application in 2021
Figure 3. Global Circulating Tumor Cell Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Circulating Tumor Cell Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Circulating Tumor Cell Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Circulating Tumor Cell Revenue in 2021
Figure 8. By Type - Global Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 9. By Application - Global Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 10. By Region - Global Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 11. By Country - North America Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 12. US Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 16. Germany Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 17. France Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 24. China Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 28. India Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 30. Brazil Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Circulating Tumor Cell Revenue Market Share, 2017-2028
Figure 33. Turkey Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Circulating Tumor Cell Revenue, (US$, Mn), 2017-2028
Figure 37. Menarini-Silicon Biosystems Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Qiagen?Adnagen? Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Clearbridge Biomedics Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Celsee Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Fluidigm Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. ApoCell Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Greiner Bio-one Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Advanced Cell Diagnostics Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Aviva Biosciences Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Fluxion Biosciences Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Sysmex Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Epic Sciences Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Cynvenio Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. CytoTrack Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Ikonisys Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Vortex BioSciences Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Gilupi Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Biocept Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. ScreenCell Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. ANGLE Circulating Tumor Cell Revenue Year Over Year Growth (US$, Mn) & (2017-2022)